RecruitingNot ApplicableNCT06445361
Prevalence of NAFLD in T1DM Patients
The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium
Sponsor
Ziekenhuis Oost-Limburg
Enrollment
138 participants
Start Date
Jul 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
To determine the prevalence of NAFLD in T1DM patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- T1DM
- ≥ 18 years of age
- Written informed consent obtained
Exclusion Criteria2
- Excessive alcohol use
- Exclusion of other causes of liver disease and secondary causes of liver steatosis
Interventions
DIAGNOSTIC_TESTFibroScan
Performance of a FibroScan measurement to determine steatosis and fibrosis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06445361
Related Trials
Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients
NCT063246044 locations
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
NCT060148791 location
Intervention for Children With Type 1 Diabetes Targeting Gut Microbes
NCT061987251 location
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
NCT072121791 location
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
NCT0706157411 locations